The Fed is expected to cut rates Wednesday, but it is unlikely to tell markets what they want to hear on future rate cuts.Market Insiderread more
The trade war between the United States and China has lasted for more than one year — and a resolution is nowhere in sight.World Economyread more
Pelosi said Trump should not have tried to address China's trade practices in a way that opened Americans up to financial pain.Politicsread more
Here's CNBC review of the Apple Watch Series 5, which makes a step forward with an always-on display and a useful compass that can help you find your way on Apple Maps.Technologyread more
On Sept. 18, Capital One and Walmart announced the launch of the Capital One Walmart Rewards Credit Card Program, which offers two new cobranded credit cards. Here's a break...Moneyread more
TransferWise posted an annual net profit of £10.3 million on revenues of £179 million.Technologyread more
In an apparent setback for Prime Minister Benjamin Netanyahu, exit polls show the Israeli leader has fallen short of securing a parliamentary majority with his hard-line...World Newsread more
President Donald Trump doesn't want war with Iran — but Tehran seems inclined to "test the Trump administration," says Gerald Feierstein, a former U.S. Ambassador to Yemen.Oilread more
Live the high life with a night's stay at Highclere Castle, the iconic stately home made famous by Downton Abbey.Spendread more
Large banking institutions face the risk of failure if interest rates in Europe continue to stay negative, warns the global chief economist of the Economist Intelligence Unit.Banksread more
The fallout from two fatal crashes of Boeing 737 Max planes has ensnared the manufacturer's most-loyal customer: Southwest Airlines. The carrier has canceled thousands of...Airlinesread more
Jefferies' research team named its favorite picks of biotech stocks that are expected to have good news in the coming months.
"Biotech continues its Road to Repair and is near 1-year highs," wrote Jefferies analyst Michael Yee in Thursday's note to clients. Scrutiny over the sector's pricing practices has subsided, general interest in the sector has picked up, and there is recent M&A activity, he said.
"Our thesis continues to be the sector has been beaten down for 2 years and [is] pretty cheap vs health care and broader market."
Jefferies said that the industry's ever-improving backdrop coupled with a shift in investor focus to fundamentals bodes well for the sector.
Here are four companies that made Jefferies' recommended list and the firm's price targets for each.